About Us
Intellectual Property
NeuroRepair owns certain pending patent applications respecting at least one proprietary molecule, and other applications respecting the use of Transforming Growth Factor-alpha for treatment of central nervous system disorders and injuries, including stroke, Alzheimer’s disease, Parkinson disease, spinal cord injury, retinal disorders, and brain injury from head trauma.
Pipeline
Transforming Growth Factor-alpha
TGFα is an endogenous 50 amino acid growth factor with no posttranslational modifications. TGFα has been shown to protect against acute neuronal cell death in animal models of stroke. NeuroRepair is currently developing TGFα applications for the treatment of acute and chronic stroke and plans to begin preclinical testing in primates.
Future Indications
TGFα also induces massive proliferation, migration
and differentiation of new neurons in the damaged adult brain. The degree
of proliferation and migration is orders of magnitude over any other growth
factor or synthetic small molecule.
In the long term, NeuroRepair plans to develop applications respecting
the use of TGFa for treatment of central nervous system disorders and
injuries, including stroke, Alzheimer’s disease, Parkinson disease, spinal
cord injury, retinal disorders, and brain injury from head trauma.
Rats receiving an infusion
of TGFa after brain injury to the striatum (cartooned in purple) demonstrate
massive proliferation of stem cells in the subventricular zone (SVZ) which
migrate in a ridge toward the site of the injury. New cells express markers
of differentiating glial cells and neurons.Adapted from Fallon et al., 2000
2006 © NeuroRepair, Inc. All rights reserved.